Meeting Impression | Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?
See below to download the Meeting Impression
The aim of this educational program was to provide a balanced overview of results with a novel approach to reduce residual CV risk in patients with increased cardiovascular and renal risk, namely BET inhibition. BET refers to a bromodomain and extra-terminal domain of regulatory proteins. Its inhibition modifies gene expression via epigenetic mechanisms.
This symposium was held during the 54th ERA EDTA Congress in Madrid, Spain on June 5, 2017. It was chaired by Vincent M Brandenburg, MD (Aachen, Germany) and Carmine Zoccali, MD (Reggio Cal, Italy).
The educational objectives of this symposium were to:
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Luis M Ruilope, MD, Hospital 12 de Octubre Madrid, Spain : The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?
Marta Ruiz-Ortega, PhD, Fundación Jiménez Díaz,Madrid, Spain : Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease
Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA : BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
The symposium was supported by an unrestricted educational grant from Resverlogix Corp